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Abstract
GM-CSF is important in regulating acute, persistent neutrophilic inflammation in certain settings,
including lung injury. Ligand binding induces rapid internalization of the GM-CSF receptor
(GM-CSFR𝛼) complex, a process essential for signaling. Whereas GM-CSF controls many aspects
of neutrophil biology, regulation of GM-CSFR𝛼 expression is poorly understood, particularly the
role of GM-CSFR𝛼 in ligand clearance and whether signaling is sustained despite major down-
regulation of GM-CSFR𝛼 surface expression. We established a quantitative assay of GM-CSFR𝛼
surface expression and used this, together with selective anti-GM-CSFR antibodies, to define
GM-CSFR𝛼 kinetics in human neutrophils, and in murine blood and alveolar neutrophils in a lung
injurymodel. Despite rapid sustained ligand-inducedGM-CSFR𝛼 loss from the neutrophil surface,
which persisted even following ligand removal, pro-survival effects of GM-CSF required ongoing
ligand-receptor interaction. Neutrophils recruited to the lungs following LPS challenge showed
initially high mGM-CSFR𝛼 expression, which along with mGM-CSFR𝛽 declined over 24 hr; this
was associated with a transient increase in bronchoalveolar lavage fluid (BALF) mGM-CSF con-
centration. Treating mice in an LPS challenge model with CAM-3003, an anti-mGM-CSFR𝛼 mAb,
inhibited inflammatory cell influx into the lung and maintained the level of BALF mGM-CSF. Con-
sistentwith neutrophil consumptionofGM-CSF, humanneutrophils depleted exogenousGM-CSF,
independent of protease activity. These data show that loss of membrane GM-CSFR𝛼 following
GM-CSF exposure does not preclude sustained GM-CSF/GM-CSFR𝛼 signaling and that this
receptor plays a key role in ligand clearance. Hence neutrophilic activation via GM-CSFRmay play
an important role in neutrophilic lung inflammation even in the absence of high GM-CSF levels or
GM-CSFR𝛼 expression.
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1 INTRODUCTION
Neutrophils are a key component of the inflammatory response and
play a central role in the pathogenesis of the acute respiratory dis-
Abbreviations: (m)GM-CSFR𝛼/𝛽 , (murine) granulocyte-macrophage colony stimulating factor receptor-𝛼/𝛽; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; BALF,
bronchoalveolar lavage fluid.
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tress syndrome (ARDS).1 Indeed, the extent and duration of alveolar
airspace neutrophilia in ARDS is a strong predictor of outcome.2
Whereas the presence of neutrophils within an inflamed tissue does
not mandate a pathogenic role for these cells, in ARDS we and others
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have shown that the neutrophils within the alveolar airspace have a
highly primed and pro-survival phenotype with enhanced superoxide
anion and protease release, preserved neutrophil-extracellular trap
(NET) formation, and delayed apoptosis3,4 and as such are considered
to be important drivers of lung injury.
GM-CSF is a 14.7 kDa heavily glycosylated protein, and one of
the four recognized myeloid CSFs. GM-CSF is produced from a
variety of cells including monocyte/macrophages, T cells, fibroblasts,
and lung epithelial cells5,6 and as well as being a key myeloid growth
factor, has important functional effects on a range of fully mature
cells including neutrophils, monocytes, and eosinophils. This cytokine
is also essential for alveolar macrophage function7,8 and lung surfac-
tant homeostasis.9,10 Ligand binding to its receptor GM-CSFR𝛼 results
in dimerizationwith, and signaling via, theGM-CSFR𝛽 chain, also called
the common 𝛽 receptor, which is sharedwith the IL-3 and IL-5 cytokine
signaling pathways.11,12 Activation of this receptor complex results
in JAK-mediated receptor tyrosine phosphorylation and subsequent
interaction with a Shc adaptor protein and GRB2/SoS complex to
initiate signaling.13
As well as stimulating myeloid cell proliferation and granulocyte
release from the bone marrow,14 GM-CSF has effects on a number
of other neutrophil functions including (i) up-regulation of IgA FcR,
FMLPR, CD11b and LTB4 receptor expression; (ii) enhanced chemo-
taxis, phagocytosis, release of LTB4 and arachidonic acid, and NOX2-
mediated superoxide anion generation; and (iii) a marked pro-survival
effect mediated by PI3K-dependent inhibition of apoptosis.15,16
Indeed, GM-CSF, which is found in abundance during the very early
phase of most forms of acute lung injury, has been shown to be the
dominant factor inhibitingneutrophil apoptosis in thealveolar airspace
of patients with ARDS.3
It is therefore reasonable to propose that GM-CSF acting at GM-
CSFR𝛼 in the lungs of patients with nonviral-mediated ARDS could be
playing a central role in the exuberant immune response evident in the
lungs during ALI. However, in cell lines transfected with or selected
for high constitutive expression of GM-CSFR𝛼, it has been shown that
ligand binding induces rapid and substantial receptor internalization
(t1/2 = 11 ± 4 min in erythroblast TF-1 cells; 8 ± 2 min in FD-hGMR
(FDCP-1 cells overexpressing human GM-CSFR) cells, a mouse fibrob-
last cell line expressing human GM-CSFRs).17 Likewise, agonism of
the cytokine-specific GM-CSF𝛼 chains in TF-1-F11 (TF-1 cells selected
for high expression of GM-CSFR) cells causes marked proteasome-
dependent degradation of the GM-CSF𝛽 common 𝛽 chain,18 which
terminates signaling via the receptor complex. One further key, and
as yet unresolved question, is whether the very transient nature of
the increased alveolar GM-CSF levels seen in ARDS reflects tran-
sient GM-CSF generation and/or persistent production but enhanced
ligand clearance.
Addressing this question, and understandingGM-CSFRdynamics in
human neutrophils, especially in those cells recovered from an inflam-
matory setting, is therefore crucial to further establish a predominant
role for GM-CSF in ALI. For example, internalization of the GM-CSFR𝛼
might lead to cessation of GM-CSF signaling and predict an early loss
of GM-CSF mediated effects; in contrast, if the GM-CSFR𝛼 complex
remains highly active despite a reduction in cell surface abundance
and plays a key role in ligand removal, then single time point measures
of GM-CSF abundance and/or GM-CSFR𝛼 expression in clinical sam-
ples might severely underestimate the functional importance of this
signaling pathway.
To address this, we established a new quantitative assay of GM-
CSFR𝛼 expression to study GM-CSFR𝛼 kinetics in human neutrophils
and used a murine lung injury model to explore the dynamics of
GM-CSFR𝛼 expression in blood and alveolar neutrophils in vivo. Our
data show that loss of cell membrane GM-CSFR𝛼 following GM-CSF
does not preclude sustained GM-CSF/GM-CSFR𝛼 signaling and that
this receptor plays a key role in ligand clearance. These findings have
important implications for the interpretation of translational data
such as GM-CSF concentrations measured in disease samples, and of
studies investigating the pathogenesis of neutrophilic disease using
GM-CSFR𝛼 blockade.
2 MATERIALS AND METHODS
2.1 Study participants
Human peripheral blood neutrophils were isolated from adult healthy
non-medicated volunteers. Neutrophils were also isolated from the
blood and the bronchoalveolar lavage fluid (BALF) of patients requir-
ing mechanical ventilation for ARDS as previously detailed.4 All stud-
ies complied with the Declaration of Helsinki and were approved
by the Cambridge Research Ethics Committee (08/H03306/17);
written informed consent was obtained from all subjects or their
legal surrogate.
2.2 Isolation of human neutrophils
Peripheral neutrophils were isolated from sodium citrate anti-
coagulated venous blood, using dextran sedimentation and discon-
tinuous Percoll gradients as described19 and resuspended in IMDM
supplemented with 10% human serum and penicillin/streptomycin.
BALF neutrophils were isolated by negative selection (Robosep).4,15
The purity of the isolated blood neutrophils was > 95%, with less than
1%mononuclear cells and 4% eosinophils.
2.3 TF-1 cell viability assays
TF-1 cells (erythroleukemic cell line; R&D Systems, Abingdon,
UK) maintained in 4 ng/ml human GM-CSF (as supplier’s instruc-
tions, in RPMI-1640 with 5% FBS (heat inactivated) and peni-
cillin/streptomycin) were washed 3 times to ensure complete removal
of GM-CSF. The cells were then treated with 0.25 ng/ml GM-CSF
(R&D Systems), in the presence or absence of a serial dilution of
CAM3001 (blocking antibody specific to human GM-CSFR𝛼, MedIm-
mune Ltd, Cambridge, UK) or isotype control (NIP228, MedImmune),
with both ligand and antibody being added at the same time to the
cultures. The cells were incubated for 72 hr. CellTiter-Glo (Promega
UK, Southampton, UK, G7570) was used to measure ATP as an
indirect measure of the number of viable cells according to the
manufacturer’s instructions.
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2.4 Quantification of GM-CSFR𝜶
TF-1 cells (R&D Systems) that had been maintained in human GM-
CSF (4 ng/ml, R&D Systems) were washed 3 times to remove GM-CSF.
GM-CSFR𝛼 expression was assessed on the cells following culture for
a further 18 hr in the presence or absence of GM-CSF (4 ng/ml).
GM-CSFR𝛼 expression was quantified on human neutrophils cul-
tured in the presence of GM-CSF (0.001-10 ng/ml, R&D Systems),
LPS (100 ng/ml, Sigma Aldrich UK, Poole, UK), TNF𝛼 (20 ng/ml, R&D
Systems) or appropriate vehicle control. In certain experiments neu-
trophils were pretreated for 30 min with CAM-3001 (blocking anti-
body specific to human GM-CSFR𝛼) or for 1 hr with the proteaso-
mal inhibitor MG132 (20 𝜇M, Sigma Aldrich), brefeldin A (10 𝜇g/ml)
to block lysosomal degradation, or the transcriptional inhibitor acti-
nomycin D (2 𝜇g/ml); in certain experiments IL-8 was measured in the
supernatants using an in-house ELISA.20 GM-CSFR𝛼 levels were also
quantified on blood neutrophils and BALF neutrophils derived from
patients with ARDS.
2.4.1 Flow cytometry
Pelleted TF-1 cells were resuspended in 100 𝜇l FACS buffer (eBio-
science, ThermoFisher Scientific UK, Loughborough, UK supple-
mented with 0.1 𝜇M EDTA) containing anti-human GM-CSFR𝛼
(CD116) antibody or isotype control (both BD Pharmingen, BD Bio-
science, Wokingham, UK) (0.5 𝜇g/stain) for 30 min in the dark on ice.
TF-1 cells were then washed in FACS buffer and fixed with 200 𝜇l 4%
formaldehyde in PBS for 10 min at RT and analyzed by flow cytometry
(LSRII Fortessa, BD Biosciences).
Pelleted neutrophilswere resuspended in 100𝜇l FACSbuffer (eBio-
science, supplemented with 0.1 𝜇M EDTA) containing phycoerythrin
(PE)-mouse anti-human GM-CSFR𝛼 (CD116) antibody (0.04 𝜇g/ml)
(BD Pharmingen) for 30 min in the dark on ice. Neutrophils were then
washed in FACS buffer and fixed with 500 𝜇l 4% formaldehyde in PBS
for 10 min at RT and analyzed by flow cytometry (LSRII Fortessa, BD
Pharmingen). To determine the absolute number of GM-CSFR𝛼 copies
expressedperneutrophil, themean fluorescence intensity (MFI) values
for CD116 (GM-CSFR𝛼) staining were interpolated against a standard
curve obtained by staining 5 bead populations concurrently (1 blank
and4with increasing antibody binding capacity) (QuantumSimplyCel-
lular anti-mouse IgG, Bangs Laboratories, Fishers, Indiana, USA) (Sup-
plemental Fig. S1). These microspheres acted as external standards
to enable the standardization of fluorescence intensity units irrespec-
tive of the detecting instrument, settings or software. Unknowns were
read against the calibration curve using the manufacturer’s QuickCal
analysis template, after confirmation of detection threshold and lin-
earity. Auto-fluorescence of neutrophils accounted for a portion of the
observed fluorescence intensity and this was corrected for by subtrac-
tion of the interpolated receptor number from a parallel neutrophil
control, minus CD116 antibody (unstained).
2.4.2 Confocal microscopy
Cytospins of freshly isolated healthy volunteer blood neutrophils were
prepared,21 stained with AlexaFluor647-CAM-3001 (1:100 dilution;
MedImmune) and mounted with Pro-Long Gold Anti-Fade Mountant
with DAPI (ThermoFisher Scientific, Loughborough, UK) prior to imag-
ing (Leica TCS SP5).
2.5 GM-CSFR𝜶mRNA analysis
Total RNA was isolated from neutrophils purified from 10 healthy vol-
unteer donors (treated for 6 hr in the presence or absence of 1 ng/ml
recombinant human GM-CSF) using TRI-reagent (Sigma, Aldrich, UK)
and RNeasy mini-columns (Qiagen, Manchester, UK); complimentary
DNA (cDNA) was prepared, fragmented, labelled and hybridized onto
GeneChip Human Genome U133 Plus 2.0 oligonucleotide arrays as
detailed.4 The data, as submitted on GSE76293, were processed using
R/Bioconductor and normalized using RMA from the “affy” package.
The fold change values, and the negative logarithm of the adjusted
P values were computed using the “limma” package, where empiri-
cal Bayes statistics and the Benjamini-Hochberg correction method
were used.
2.6 Assessment of neutrophil apoptosis in vitro
Neutrophils were cultured for 20 hr with GM-CSF, CAM-3001 (1 𝜇M),
or buffer (as detailed above) and apoptosis assessed by flow cytometry
following double staining with FITC-Annexin V and PI (FITC-Annexin
V Apoptosis Detection kit I, BD Pharmingen).22 Apoptotic neutrophils
were identified as being Annexin V positive and PI negative. Previous
studies from our group had confirmed the tight agreement between
apoptosis values obtained in neutrophils using thismethod and several
other standard assessments of apoptosis including direct morphologic
quantification.16,21
2.7 LPS-induced lung injury
Pathogen-free female C57BL/6 or BALBc/JBomTac mice were
obtained from Charles River Laboratories, Margate, UK or Taconic
Europe, Laven, Denmark, respectively, and studied at 8–9 weeks of
age with a body weight of circa 20 g. Mice were supplied with food
and water ad libitum and observed carefully after the LPS challenge
for any adverse effects. In vivo procedures performed in the United
Kingdomwere conducted under the authority of a HomeOffice issued
Project License in accordancewith the Animals [Scientific Procedures]
Act 1986with appropriate ethical approval, and procedures in Sweden
conductedunderAZpermit number 31–11684/08 and ethics approval
M104/08; group sizes were determined either using the MFI for GM-
CSFR𝛼 in BALF neutrophil numbers or total cell influx to LPS seen in
preliminary studies, with 𝛼 set at 0.05, 𝛽 to 0.2, and power to 80%. LPS
was delivered where indicated via nebulized aerosol to induce lung
inflammation. LPS, P. aeruginosa, serotype 10, phenol extracted (Sigma
Aldrich), was dissolved in physiologic saline (9 mg/ml NaCl). The mice
were placed in a semi-open inhalation box (max. 10 mice) and exposed
once to nebulized aerosol of P. aeruginosa LPS (1 mg/ml) for 10 min.
The aerosol was generated by a Pari LC Jet Star nebulizer, using 5 ml
LPS suspension and a flow of 5 l/min (pressure = 2 Bar). The control
groupwas exposed to saline according to the same procedure. Animals
were dosed intranasally (i.n.) with CAM-3003 or isotype control 3 hr
before LPS challenge. Budesonide control was administered (3 mg/kg
p.o.) 3 hr prior to LPS challenge.
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In other instances, lung inflammation was induced by instillation of
10 𝜇g LPS (E. coli 026:B6, Sigma Aldrich) per mouse delivered i.n. in
25 𝜇l of PBS (vehicle control) to groups of 6 mice under light isoflu-
rane anesthesia,23 the optimal dose having previously been confirmed
in a study comparing 0.1, 1, or 10 𝜇g per mouse (data not shown).
In some experiments, mouse groups were treated with CAM-3003
(mouse equivalent to CAM-3001, MedImmune, Lot SP08-013; 400 𝜇g
in 40𝜇l, i.n. as above) or PBS3hr prior, or 6 hr following, LPS instillation
(10 𝜇g LPS).
Mice were terminally anesthetized via intraperitoneal administra-
tion of Euthatal at 3, 6, or 24 hr post LPS and blood drawn from the
vena cava. BALF was collected via an endotracheal cannula placed
proximal to the larynx and aliquots of recovered PBS (approx. 1 ml
total) were pooled and used for cytokine profiling, flow cytometry, and
cytospins. Cytospins (Shandon Cytospin 3) from BALF were methanol
fixed and stainedwithREASTAINQuick-Diff Kit (Reagena, Toivala, Fin-
land). Femurs were collected, and the bone marrow flushed to col-
lect cells for flow cytometry. A staggered dosing strategy was used to
ensure that all cellular samples were collected, stained and analyzed in
parallel where required.
2.8 Assessment of LPS-induced lung injury
Total and differential cell counts were quantified either using
cytospins, and/or (following red blood cell lysis) blood, BALF and bone
marrow samples were stained with a panel of fluorescent antibodies
and the percentage of neutrophils calculated: BUV395-CD45 (4𝜇g/ml,
clone 30-F11, BDHorizon, BD Bioscience,Wokingham, UK), BUV421-
Ly6G (12 𝜇g/ml, clone 1A8, BD Horizon), PE-Ly6C (12 𝜇g/ml, clone
AL-21, BD Pharmingen), and eF780 viability dye (1:1000 dilution,
eBioscience). The cells were fixed in 4% formaldehyde before being
analyzed (LSRII Fortessa, BD Horizon). Neutrophils were identified as
CD45+, Ly6G high, CD11b high and Ly6C low. In addition, a total cell
count was performed on BALF by flow cytometry following a 1:9 dilu-
tion in PBS (MACSQuant, Bergisch Gladbach, Germany); leukocytes
were identified by their characteristic FSC/SSC distribution.
Mouse GM-CSF in BALF was measured by ELISA (DuoSet ELISA
kits, R&D Systems) and IL-1𝛽 in lung homogenate was measured
using MSD multiplex analysis (Mouse Pro-inflammatory 7-plex,
MesoScale Discovery, Rockville, Maryland, USA).
2.9 Measurement of murine GM-CSFR𝜶 and
GM-CSFR𝜷 expression in neutrophils
GM-CSFR𝛼 and 𝛽 expression was quantified in mouse BALF, blood and
bonemarrow neutrophils by flow cytometry and expressed as theMFI
geometric mean. Cells were stained for GM-CSFR𝛼 with APC-CAM-
3003 (labelled with Lightning-Link APC as per the manufacturer’s
instructions, InnovaBiosciences, Cambridge, UK), GM-CSFR𝛽 with PE-
CD131 (JORO50, BDPharmingen), andBUV395-CD45 (4𝜇g/ml, clone
30-F11, BDHorizon), BV421-Ly6G (12 𝜇g/ml, clone 1A8, BDHorizon),
AlexaFluor488-Ly6C (12 𝜇g/ml, clone HK1.4, Biolegend, San Diego,
California, USA), AlexaFluor488-CD11b (12 𝜇g/ml, clone M1/70, BD
Pharmingen) and eF780 viability dye (1:1000dilution, eBioscience). All
flow cytometry was performed on one day on a single instrument for
each study.
2.10 In vitro ligand depletion
Human neutrophils were cultured in the presence of GM-CSF (30
pg/ml, R&D Systems) or vehicle alone and supernatant was collected
over a 24 hr time course. Where appropriate, cells were pretreated
(30 min) with Sivelestat (10 𝜇M, Sigma Aldrich) and EDTA (R&D Sys-
tems). The level of GM-CSF remaining in the supernatant was deter-
mined by ELISA (R&D Systems).
2.11 Statistical analysis
Data are expressed as mean ± SEM for (n) separate experiments, each
conducted in triplicate unless otherwise indicated. Assessment of
statistical difference was undertaken by 2-way ANOVA with Bonfer-
roni’s test adjusted for multiple comparisons and a P value of < 0.05
considered significant.
3 RESULTS
3.1 GM-CSFR𝜶 quantification and kinetics
following GM-CSF treatment
We first observed that an antagonistic anti-GM-CSFR𝛼 antibody
(CAM-3001) dose dependently inhibited the ability of GM-CSF to pro-
tect against TF-1 cell apoptosis (Fig. 1A), and yet GM-CSFR𝛼 was
barely detectable on the cell surface of cells that had been cultured
with GM-CSF (Fig. 1B). Once GM-CSF had been withdrawn for 18 hr,
GM-CSFR𝛼 was then detectable at the cell surface (Fig. 1B). These
data were consistent with previously published data suggesting that
GM-CSF drives the internalization of its own receptor. Given that the
antibodies and GM-CSF were added together to the TF-1 viability
assays, this raised questions as to how CAM-3001 acts as an effec-
tive inhibitor when its target is actively down-regulated by the ligand,
and how receptor kinetics might impact its therapeutic use. In view of
this, we designed experiments in a therapeutically relevant context to
explore this question inmore detail.
Measurement of GM-CSFR𝛼 expression in human neutrophils is
readily achievable using confocal imaging (Fig. 2A) or standard flow
cytometry using GM-CSFR𝛼-selective antibodies. However, for more
accurate quantification of cell surface GM-CSFR𝛼 number we uti-
lizedmicrosphereswith knownbinding affinities as external standards,
which enables the standardization of fluorescence intensity units irre-
spective of staining variability between experiments, instrument, and
software (Supplemental Fig. S1). This approach was considered of
importance for measurements made in patient-derived neutrophils.
After correction for nonspecific staining, a mean surface GM-CSFR𝛼
number of 7141± 474 (mean± SEM; n= 28) receptors per cell was cal-
culated (Fig. 2B).
Following stimulation of isolated neutrophils with 1 ng/ml GM-CSF,
we observed amarked and time-dependent reduction inmean cell sur-
face GM-CSFR𝛼 number, decreasing by 64% (P < 0.001) 30 min after
stimulation, and by 89% (P < 0.001) at 2 hr (Fig. 2C). A more modest
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F IGURE 1 GM-CSFR blockade and quantification in TF-1 cell line.
(A) TF-1 cells,washed to remove residual human recombinantGM-CSF
from the routine culture conditions, were treatedwith 0.25 ng/ml GM-
CSF, in the presence of a serial dilution of CAM3001 or isotype control
and cultured for 72 hr. CellTiter-Glo was used to measure ATP as an
indirectmeasure of number of viable cells. Data representmean± SEM
of n = 4 independent experiments. (B) TF-1 cells that had been main-
tained in 4 ng/ml human GM-CSF were washed three times to ensure
complete removal of GM-CSF. The cells were then returned to cul-
ture in the presence or absence of 4 ng/mL human GM-CSF for 18 hr.
The cells were stained with CAM3001 followed by PE-conjugated sec-
ondary antibody to assess surface levels of GM-CSFR𝛼. In the cells
that had been cultured in the absence of GM-CSF the GM-CSFR𝛼 was
detectable above background. In the cells that had been maintained in
GM-CSF theGM-CSFR𝛼was considerably lower. Image shown is a rep-
resentative experiment of four independent experiments
loss of cell surface GM-CSFR𝛼 number was observed when the cells
were stimulated with TNF𝛼 (20 ng/ml) or LPS (100 ng/ml); in addition,
this effect was noticeably slower (P< 0.05 at 2 hr; Fig. 2C).WhenGM-
CSF was removed after 30 min by washing, GM-CSFR𝛼 number failed
to recover, suggesting that cell surface GM-CSFR𝛼 numbers were
either not recycled or recycled only very slowly after withdrawal of
ligand (Fig. 2D).
Interrogation of our recently generated human neutrophil tran-
scriptomic data set, generated using neutrophils isolated in an iden-
tical way and treated with human recombinant GM-CSF at 1 ng/ml
for 6 hr (GEO accession number GSE76293), revealed a 1.9-mean fold
increase in GM-CSFR𝛼 mRNA abundance using 4 independent probes
for the GM-CSFR𝛼 (mean adjusted P = 8.7 × 10−5; Table 1). This con-
trasts to the verymajorGM-CSF stimulated increase (25-fold) inCD69
mRNA (Table 1) (Zhang et al., 2004). Together, these data indicate that
GM-CSFR𝛼 is rapidly lost from the neutrophil cell surface following
GM-CSF stimulation, and to a lesser extent, following LPS and TNF𝛼;
whereas GM-CSF stimulation appears to increase GM-CSFR𝛼 tran-
scription, this was not associated with early recovery of cell surface
GM-CSFR𝛼 expression after ligand removal.
Previous studies have suggested roles for both the lysosome and
proteasome in the related CSF receptor G-CSFR𝛼 ligand-mediated
internalization,25 and for similar mechanisms to operate for the
shared common 𝛽 chain.18 However, we were unable to block GM-
CSF-mediated GM-CSFR𝛼 internalization nor GM-CSF mediated IL-8
release with MG132 (cell-permeable proteasome inhibitor), and like-
wise actinomycin D and brefeldin A had no effect on receptor inter-
nalization (Supplemental Fig. S2). Proteosomal degradation, recycling
from the golgi or endosomal compartments, and lysosomal degrada-
tion do not therefore appear to affect GM-CSFR𝛼 cell surface kinetics.
3.2 The pro-survival effect of GM-CSF in
neutrophils requires prolonged GM-CSFR𝜶
stimulation
Given the above data, which show that neutrophils lose approximately
90% of their cell surface GM-CSFR𝛼 when stimulated with GM-CSF
for 2 hr, we wished to examine if this correlated with a loss of recep-
tor signaling at longer time points. The functional read out of GM-
CSF-induced inhibition of constitutive (time-dependent spontaneous)
apoptosis was chosen, which can be readily assessed in vitro using dual
Annexin V and PI staining. Hence neutrophilsmaintained in the contin-
uous presence of GM-CSF for 20 hr at 37◦C show a marked (> 70%)
and concentration-dependent (EC50 0.03 ng/ml; n = 8) inhibition of
apoptosis (Fig. 3A). When these cells were pretreated with 0.01–
1000 nMCAM-3001, a humanGM-CSFR blocking antibody, this effect
was completely abolished, again in a concentration-dependent man-
ner (IC50 CAM-3001 inhibition of GM-CSF treatment 0.05± 0.03 𝜇M;
n = 3) (Fig. 3B). Most instructively, when GM-CSF was removed by
washing 1.5 or 6 hr into these incubations, that is, at a time when
there was a profound loss in cell surface GM-CSFR𝛼 expression, the
pro-survival effect of GM-CSF was almost entirely lost (Fig. 3C); like-
wise, when CAM-3001 was added at a maximally effective concen-
tration (1 𝜇M) 1, 2, 4, and even 6 hr after GM-CSF, full inhibition of
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indicated cytokine (GM-CSF [1 ng/ml], TNF𝛼 [20 ng/ml] and LPS [100ng/ml]) beforeGM-CSFR𝛼 number/cell was assessed by flow cytometry (as for
B) at the indicated time and compared to baseline. In some experiments (D) samples treated with GM-CSF (1 ng/ml) were washed (x2) and resus-
pended in GM-CSF freemedia for the remainder of the experiment. Data represent mean± SEM of n= 3 (C) or n= 4 (D) independent experiments.
Statistical analysis was performed by 2-way ANOVAwith Bonferroni’s post-test (Significant at ***P< 0.001, **P< 0.01, *P< 0.05)
TABLE 1 Fold change in mRNA for CD69 and GM-CSFR𝜶 in neu-
trophils stimulatedwith GM-CSF for 6 hrFreshly isolated human neu-
trophils were incubated with recombinant human GM-CSF (1 ng/ml)
or vehicle control for 6 hr and cDNA prepared as previously detailed.4
Labelled cDNA was hybridized onto GeneChip Human Genome U133
Plus 2.0 oligonucleotide arrays (Affymetrix, Santa Clara, CA, USA). The
data, as submitted on GSE76293, were processed as detailed above
and the fold change values, and the negative logarithm of the adjusted
P values computed using the “limma” package, where empirical Bayes
statistics and the Benjamini-Hochberg correctionmethodwere used
Gene Probe ID
Fold
Change
–LOG
(adjPValue) adjPValue
CD69 209795_at 25.3 17.1 8.57e-18
GMCSFRA 210340_s_at 1.99 7.5 3.54e-8
GMCSFRA 207085_x_at 2.16 5.7 1.95e-6
GMCSFRA 211286_x_at 1.82 5.3 5.22e-6
GMCSFRA 211287_x_at 1.65 3.5 3.41e-4
the GM-CSF-induced pro-survival effect was still observed (Fig. 3D).
These data indicate: (i) the critical need for “sustained” GM-CSFR𝛼
signaling to affect the anti-apoptotic function of GM-CSF and (ii)
together with the very low EC50 for this response (0.03 ng/ml), a high
degree of GM-CSFR𝛼 receptor “spareness.” Hence, even substantial
receptor loss does not appear to prevent sustained and effective GM-
CSFR𝛼 signaling in the human neutrophil.
3.3 Assessment of GM-CSFR𝜶 kinetics in
inflammatory neutrophils in vivo
We next explored the dynamics of GM-CSFR𝛼 expression in inflam-
matory neutrophils to determine if time-dependent GM-CSFR𝛼
loss in these cells could be observed in vivo. This was undertaken
using an LPS-induced lung injury model in mice. We demonstrated
previously that CAM-3003, the murine equivalent to CAM-3001,
potently inhibited GM-CSF-induced proliferation of mouse FDCP
cells in a dose-dependent manner and reduced smoke-induced lung
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F IGURE 3 Sustained GM-CSF signaling required for GM-CSF-mediated neutrophil survival. (A–D) Freshly isolated neutrophils were treated
with the indicated concentration of GM-CSF and the percentage of apoptotic cells analyzed after 20 hr culture by flow cytometry. (B) Neutrophils
were pretreated with increasing concentrations of CAM-3001 for 20 min prior to GM-CSF treatment. (C) Cells were maintained in media con-
taining the indicated concentration of GM-CSF or the culture media were replaced after 1.5 or 6 hr of treatment with GM-CSF-free media for the
remainder of the incubation time. Media change alone did not impact apoptosis of control samples without GM-CSF incubation (data not shown).
(D) Human neutrophils were treated with GM-CSF (1 ng/ml) and this was followed by addition of CAM-3001 (1 𝜇M) at the indicated time after
GM-CSF treatment began. The bars indicate the response to GM-CSF and the effect of pretreatment with CAM-3001 (20 min) prior to treatment
with GM-CSF. Data represents mean± SEM of n= 8 (A), n= 3 (B), n= 5 (C) or n= 3 (D) independent experiments
inflammation.26 Supporting a role for GM-CSF signaling in acute lung
injury,we show thatCAM-3003 significantly reduced the influx of total
inflammatory cells to the lung in response to inhaled LPS (35± 10% for
100 𝜇g i.n. dose; 48 ± 8% reduction for 400 𝜇g i.n. dose in total BALF
cells compared to isotype control) (Fig. 4A), which consisted predom-
inantly of neutrophils (37± 8% for 100 𝜇g i.n. dose; 50± 8% reduction
for 400 𝜇g i.n. dose in BALF neutrophils compared to isotype control)
(Fig. 4B). In addition, CAM-3003 reduced LPS- induced lung concen-
trations of IL-1𝛽 (Fig. 4C), IL-6, TNF𝛼, andCXCL2 (data not shown).We
hypothesized that the use of CAM-3003 would allow us to determine
the role of GM-CSFR𝛼 in ligand removal in the inflamed lung.
Following i.n. instillation of LPS, the percentage of neutrophils in
the BALF increased in a time-dependent manner from< 1% in the PBS
control group to 70± 8%, 90± 2% and 90± 2% at 3, 6, and 24 hr post-
LPS, respectively. This was associated with a blood neutrophilia and
small but consistent decline in the overall percentage of neutrophils
within the bone marrow (baseline 38 ± 2% neutrophils; 24 hr after
LPS 26 ± 1% neutrophils; P < 0.01; Fig. 5A). The concentration of
GM-CSF in the BALF peaked 3 hr after LPS treatment (294± 34 pg/ml)
but declined thereafter to near baseline values by 24 hr (Fig. 5B).
Of note, this reduction in BALF GM-CSF at 24 hr was significantly
attenuated following the administration of CAM-3003 administered
8 DEALESSANDRIS ET AL.
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F IGURE 4 GM-CSFR𝜶 blockade inhibits inflammation in response to inhaled LPS in a mouse model of acute lung injury.Mice were treated
with inhaled PBS or LPS (nebulized 1 mg/mL for 10 min) and 24 hr later BALF total cell counts (A), BALF neutrophils (B) and lung homogenate
IL-1𝛽 (C) were assessed 24 hr after LPS challenge. Additionally, mice were treated intranasally with PBS, isotype control, or CAM-3003 (at doses
indicated), or budesonide (3 mg/kg, p.o.) 3 hr prior to LPS exposure as indicated. n = 8 mice per group, except control groups without LPS (n = 4
mice per group). Statistical analysis was performed by 2-way ANOVAwith Bonferroni’s post-test (Significant at ***P < 0.001, **P < 0.01, *P < 0.05
compared to either PBS group, isotype control or LPS group as indicated by bars)
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F IGURE 5 GM-CSFR𝜶 blockadecauses a sustained increase in LPS-
induced alveolar GM-CSF concentration.Micewere treatedwith PBS
or LPS (10 𝜇g, intranasally [i.n.]) for the indicated time before the per-
centage of neutrophils (as a percentage of CD45+ cells) in the blood,
bone-marrow and BALF was determined by (A) flow cytometry and
(B) the concentration of GM-CSF in the BALF measured by ELISA. (C)
CAM-3003 (anti-mouse GM-CSFR𝛼 mAb) or isotype control (400 𝜇g,
i.n.) was administered either 3 hr prior or 6 hr post-LPS administra-
(continued on the next column)
either 3 hr before, or 6 hr after, the LPS challenge (Fig. 5C), implying
that the removal of GM-CSF from the airspace is at least in part
GM-CSFR𝛼-mediated.
Cell surface expression of GM-CSFR𝛼 and 𝛽 was measured on the
BALF neutrophils (CD45+, Ly6G+, CD11b+, Ly6C−) by flow cytom-
etry. We observed a time-dependent reduction in the cell surface
expression of GM-CSFR𝛼 on BALF neutrophils (Fig. 6A) following LPS
challenge. In contrast, bonemarrow neutrophils increased GM-CSFR𝛼
expression following LPS challenge (Fig. 6A). GM-CSFR𝛽 expression
was also far lower in BALF neutrophils compared to blood neutrophils
even at the earliest time point (Fig. 6B). Although Figure 6 shows the
data for GM-CSFR𝛼 and GM-CSFR𝛽 expression in BALF neutrophils
following PBS challenge, the extremely small number of neutrophils
recovered in this control group of animals makes accurate quan-
tification of GM-CSFR𝛼 and 𝛽 in these cells challenging and hence
uncertain. Figure 6 also suggests a dissociation in the time-course for
GM-CSFR𝛼 and 𝛽 loss from the neutrophil cell surface, with faster
kinetics observed for the common 𝛽 chain.
These data indicate that in GM-CSF rich environments in vivo,
GM-CSFR𝛼 and 𝛽 expression on infiltrating neutrophils is rapidly
down-regulated, the former being consistent with our human in vitro
stimulations. This hypothesis is supported by a preliminary assessment
of surface neutrophil GM-CSFR𝛼 in a small number of patients with
ARDS (n = 7) where a greater variance and lower mean receptor
number was observed in GM-CSFR𝛼 expression in BALF neutrophils
(5006 ± 1303 [mean ± SEM] GM-CSFR𝛼 receptors/neutrophil) com-
pared to GM-CSFR𝛼 expression in patient-matched blood neutrophils
(8026 ± 847 [mean ± SEM]; Supplemental Fig. S3). Blood neutrophils
from patients with ARDS when treated with GM-CSF ex vivo showed
increased survival similarly to healthy donor neutrophils (Supplemen-
tal Fig. S3) showing therewas no disease-dependent deficiency in their
GM-CSF responsiveness. The limited number of samples (purified
BALF neutrophils) available in the ARDS group precluded any further
analysis of GM-CSFR𝛼 expression.
3.4 Neutrophils deplete GM-CSF in vitro
To further support the hypothesis that neutrophils are a key contrib-
utor to GM-CSF depletion, we demonstrated the ability of human
neutrophils to deplete exogenously added recombinant human
GM-CSF (Fig. 7). The time-course of ligand depletion was consistent
with previously observed decreases in GM-CSFR and could not be
explained by ligand degradation by proteases (e.g., released by acti-
vation of neutrophils) because protease inhibitors had no impact on
ligand depletion in vitro.
We conclude that intra-alveolar concentrations of GM-CSF are
depleted by GM-CSFR𝛼-mediated consumption of ligand, as well as,
tion (10 𝜇g, i.n.) and the concentration of GM-CSF after 24 hr was
determined by ELISA. Data show mean ± SEM for each mouse group
(A, n = 6; B, n = 6; C n = 5). Statistical analysis was performed by 2-
way ANOVA with Bonferroni’s post-test (Significant at ***P < 0.001,
**P < 0.01, *P < 0.05, compared to PBS group (A and B) or LPS group
(C)). Data in A are representative of 2 independent experiments
10 DEALESSANDRIS ET AL.
0
200
400
600
0
500
1000
1500
G
M
-C
S
F
R
β 
M
F
I (
ge
o 
m
ea
n)
G
M
-C
S
F
R
α 
M
F
I (
ge
o 
m
ea
n)
BALF Whole blood Bone marrow
PB
S
3h
 L
PS
6h
 L
PS
24
h 
LP
S
PB
S
3h
 L
PS
6h
 L
PS
24
h 
LP
S
PB
S
3h
 L
PS
6h
 L
PS
24
h 
LP
S
PB
S
3h
 L
PS
6h
 L
PS
24
h 
LP
S
PB
S
3h
 L
PS
6h
 L
PS
24
h 
LP
S
PB
S
3h
 L
PS
6h
 L
PS
24
h 
LP
S
BALF Whole blood Bone marrow
A
B
**
*
***
******
***
***
***
***
***
***
***
**
*
F IGURE 6 Dynamic changes in BALF neutrophil GM-CSFR𝜶 and
common 𝜷 chain expression during LPS-induced acute lung injury.
Mice were treated with PBS or LPS (10 𝜇g, intranasally [i.n.]) for the
indicated time. The expression of GM-CSFR𝛼 (A) or GM-CSFR𝛽 (B)
was then determined, using flow cytometry, on neutrophils isolated
from BALF, whole blood and bone marrow. Data are expressed as geo-
metric mean fluorescent intensity. Data show single points as well as
mean ± SEM for each mouse group (n = 4–6). Statistical analysis was
performedby2-wayANOVAwithBonferroni’s post-test (Significant at
***P< 0.001, **P< 0.01, *P< 0.05)
we assume, by its rate of production by resident and influxing cells
while continuing to activateGM-CSFR𝛼 signaling at low surface recep-
tor numbers; thus, measurements of GM-CSF at a single time point are
unlikely to reflect the true biologic relevance of this pro-inflammatory
growth factor.
4 DISCUSSION
Whereas it is well established that GM-CSF induces a strong priming
and pro-survival effect in human neutrophils and plays an important
role in the pathogenesis of ARDS, the local interplay betweenGM-CSF
concentration, GM-CSFRdynamics, and the temporalmapping of func-
tional effects of this ligand on neutrophils has not been fully explored,
particularly in a disease-relevant context.
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F IGURE 7 Human neutrophils deplete exogenously added GM-
CSF from media independent of ligand degradation. Human neu-
trophils were treated with 30 pg/mL GM-CSF for the indicated time
before the concentration of GM-CSF was determined from cell super-
natant by ELISA. Where indicated, neutrophils were pretreated with
protease inhibitors (10 𝜇M Sivelestat and 2 mM EDTA) prior to treat-
ment with GM-CSF. Data are expressed as mean ± SEM (Data shown
are for n = 3 donors in a single experiment; another donor showed the
same effect in a further independent experiment)
Here we show that, following ligand-mediated receptor internal-
ization, neutrophil GM-CSFR𝛼 numbers at the cell surface fall to very
low levels (circa 10% of the receptor numbers seen in unstimulated
cells) within a short time frame and are not replenished following
ligand removal. A similar sustained reduction of eosinophil GM-CSFR𝛼
expression in response to GM-CSF (but not to IL-3 or IL-5) was also
observed by Gregory et al.27; however, these authors did not explore
the mechanisms of this response or examine this in an in vivo set-
ting. In our study, rather surprisingly inhibition of the proteasome did
not impact on 𝛼 chain dynamics nor GM-CSF-dependent IL-8 produc-
tion and the null effect of actinomycin D and brefeldin A also suggests
that there is little contribution from newly synthesized GM-CSFR𝛼 or
through receptor recycling.
Importantly, even very low levels of GM-CSFR𝛼 appear able to
maintain active GM-CSF signaling in neutrophils because the contin-
ued presence of the ligand was required to maintain the pro-survival
effects of GM-CSF on neutrophils despite the concomitant and major
reductions in receptor number. Despite previous published data from
theChilvers’ group demonstrating detectable pAKT activity at 60mins
after GM-CSF stimulation,16 we have been unable to demonstrate
continued signaling at longer time frames consistent with the require-
ment for sustained GM-CSFR activation for neutrophil survival, using
conventional assays measuring pAKT, pErk, pStat5, or phosphoryla-
tion of GM-CSFR𝛽 (data not shown). However, our observations are
compatible with a previous report in murine bone marrow cells that
only 10% of available GM-CSFRs need to be bound by GM-CSF to
elicit a maximal response28; therefore the signaling events that link
GM-CSFRactivity at later time pointsmay be important but also below
our detection threshold, or the signaling pathway responsible may be
undetermined. Our lines of evidence suggest a large spare receptor
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capacity for GM-CSFR in neutrophils. In in vivo models, complete
GM-CSFR blockade using an antagonist approach, or very major
lowering in the free GM-CSF concentration would be required to
induce therapeutic blockade of this axis in a neutrophil-dominated
disease process. This may also explain why the administration of
recombinant GM-CSF to patients with ALI-ARDS (to restore neu-
trophil phagocytic activity) does not worsen outcomes,29,30 that is,
the concentration of GM-CSF required tomaintain neutrophil survival
and GM-CSF-dependent cytokine release may already be sufficient to
saturate low levels of membrane GM-CSFR𝛼 andmaintain signaling.
We show that infiltrating neutrophils deplete free ligand via
a receptor-mediated event, most likely internalization. A previ-
ous report31 of receptor-mediated internalization of CXCL8 by
neutrophils in LPS-induced local skin inflammation suggests that
neutrophils may be programmed to limit pro-inflammatory signals
in the setting of infection and inflammation by local ligand deple-
tion. Mice lacking the GM-CSF receptor, but not wild-type controls,
developed high circulating levels of GM-CSF following endotoxin
challenge,32 supporting the role for receptor-ligand internalization
as a method of limiting inflammatory responses. Furthermore, loss-
of-function mutations in the human CSFRA gene lead to pulmonary
alveolar proteinosis (due to failure of alveolar macrophages to clear
surfactant) and are associated with markedly increased circulating
GM-CSF concentrations,33 suggesting that even in the absence of an
inflammatory stimulus, ligand internalization is required for GM-CSF
homeostasis. In the context of inflammation, reported time-courses
for pulmonary (BALF) GM-CSF accumulation in ALI patients have
indicated that GM-CSF concentrations are increased early in disease
but subsequently decline3; in our mouse model of LPS, the GM-CSF
levels peak at 3 hr, and thereafter diminish sharply. However, when
a receptor blocking antibody was added, either before or even 6 hr
post-LPS challenge, measured concentrations of GM-CSF in BALF
were maintained, and the antibody significantly inhibited cell influx
to the lung in a dose-dependent manner. Given that the decline in
detectable GM-CSF levels reduces in concert with the time-course
of neutrophil infiltration into the lung, it is likely that infiltrating
neutrophils are a key consumer of free GM-CSF. In support of this
hypothesis, we have been able to demonstrate rapid and significant
GM-CSF depletion (exogenously added recombinant ligand) by human
neutrophils in vitro, which is protease independent.
Our data might also suggest that receptor-mediated ligand deple-
tion is a significant factor in determining detectable concentrations of
free GM-CSF in clinical samples from the lung in other disease states
and may alter interpretation of studies that have described no or only
modest increases in the concentrations of GM-CSF in inflammatory
situations. Furthermore, ligand internalization may contribute to
temporal regulation of inflammatory responses and local tissue injury;
for example, GM-CSF confers acute protection in a mouse model of
influenza infection, but animals that continuously secrete high levels
of GM-CSF develop desquamative interstitial pneumonia that impairs
long-term recovery.34 For the same reasons, the role of GM-CSF
production and signaling may have been underestimated in several
other disease settings such as cryptogenic organizing pneumonia,
which is also characterized by intense inflammation.35 Clinical studies
using recombinant GM-CSF in ALI and other diseases are ongoing
and will help us elucidate this matter in more detail; however, our
data suggest that the degree of neutrophilic infiltrate and the precise
timing of therapeutic administration may determine the response to
such treatments. Our data could help to design more effective in vivo
studies to understand the interplay between appropriate responses to
infection, and chronic inappropriate neutrophilic responses that may
be driven by prolonged GM-CSF secretion.
In summary, these data show that GM-CSF exposure results in a
rapid and sustained loss of cell membraneGM-CSFR𝛼 yet this does not
preclude sustained G-CSF/GM-CSFR𝛼 signaling. Moreover, the GM-
CSFR𝛼 receptor appears to play a key role in ligand clearance. Hence
neutrophilic activation via GM-CSFR may play an important role in
neutrophilic lung inflammation even in the absence of high GM-CSF
levels or GM-CSFR𝛼 expression.
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